Clinical trials: Newly Diagnosed
Newly Diagnosed Ewing Sarcoma
Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma
The purpose of this study is to find out what effects, good and/or bad, the combination of irinotecan and temozolomide has on Ewing sarcoma.
- Trial name
- NCT01864109
- Testing
- Cyclophosphamide, Doxorubicin, Vincristine
- Where
- 7 sites in United States
- Volunteers
- 83 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Undiagnosed HIV Infection, Populations That Are Reluctant to Test for HIV
Expanded Social Network Recruitment to HIV Testing (E-SNRHT) Intervention to Locate Undiagnosed Cases and Reduce HIV-related Stigma
In South Africa's large generalized HIV epidemic, male-to-female transmission comprises a large proportion of transmission events, but men are much less likely to seek HIV testing, and disproportionately remain undiagnosed.
- Conditions
- Undiagnosed HIV Infection, Populations That Are Reluctant to Test for HIV, Long-term Undiagnosed HIV Infection, Individuals With Newly-diagnosed HIV Infection
- Trial name
- E-SNRHT (NCT06857071)
- Testing
- Expanded Social Network Recruitment to HIV Testing (E-SNRHT) Intervention
- Where
- South Africa
- Volunteers
- 2,480 people, healthy volunteers welcome
- Sponsor
- University of Illinois at Chicago
Newly Diagnosed FLT3 Mutated AML
Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML
A phase III randomized multi-center study designed to compare the efficacy of crenolanib with that of midostaurin when administered following induction chemotherapy, consolidation chemotherapy and bone marrow transplantation in…
- Trial name
- NCT03258931
- Testing
- Crenolanib, Midostaurin, Cytarabine
- Where
- 31 sites in United States
- Volunteers
- 214 people
- Sponsor
- Arog Pharmaceuticals, Inc.
Newly Diagnosed Mixed Phenotype Acute Leukemia (MPAL)
HVA in the Treatment of Mixed-Phenotype Acute Leukemia(MPAL).
This study aims to evaluate the safety and efficacy of homoharringtonine combined with venetoclax and azacitidine regimen (HVA) in newly diagnosed MPAL patients, providing a basis for the use of the HVA regimen in the treatment…
- Trial name
- HVA-MPAL (NCT07517510)
- Testing
- HVA
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Guangdong Second Provincial General Hospital
Newly Diagnosed, Treatment-naïve Prostate Cancer
A Multicenter, Prospective Study on the Prognostic Value of PSMA PET in Patients With Newly Diagnosed, Treatment-naïve Prostate Cancer
Brief Summary： Under the support of the PROMISE scoring criteria, PSMA PET has demonstrated significant prognostic value. However, previous studies on PSMA PET included patients with various stages of prostate cancer, and the…
- Trial name
- PSMA-VISION (NCT07474142)
- Testing
- Not provided
- Where
- 9 sites in China
- Volunteers
- 1,000 people
- Sponsor
- Xijing Hospital
Non Small Cell Lung Cancer Metastatic, Newly Diagnosed NSCLC
Liquid Biopsy Based NGS in Newly Diagnosed NSCLC
This study expands the application of an electronic health record (EHR) "nudge" used to prompt physicians' clinical practice to order molecular testing at the time of initial diagnosis for patients with specific types of advanced…
- Conditions
- Non Small Cell Lung Cancer Metastatic, Newly Diagnosed NSCLC, Non-Squamous Non-Small Cell Neoplasm of Lung
- Trial name
- iNUDGE (NCT05853887)
- Testing
- iNUDGE
- Where
- 6 sites in United States
- Volunteers
- 260 people
- Sponsor
- Charu Aggarwal
Glioblastoma, Melanoma Stage IV
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
This is an open-label, two-part, phase 1-2 dose-finding study designed to determine the safety, tolerability, PK, PD, and proof-of-concept efficacy of ST101 administered IV in patients with advanced solid tumors.
- Conditions
- Glioblastoma, Melanoma Stage IV, Breast Cancer, Prostate Cancer
- Trial name
- NCT04478279
- Testing
- ST101, Temozolomide, Radiation
- Where
- 11 sites in United States, United Kingdom
- Volunteers
- 125 people
- Sponsor
- Sapience Therapeutics
Intensive Chemotherapy Unfit, Newly Diagnosed Acute Myeloid Leukemia (AML)
Alternating Regimen of VA and Low-dose CHA in the Treatment of Unfit Newly Diagnosed AML
This phase II trial tests how well VA alternating with low-dose CHA works in treating unfit patients with newly diagnosed acute myeloid leukemia (AML).
- Conditions
- Intensive Chemotherapy Unfit, Newly Diagnosed Acute Myeloid Leukemia (AML), Age ≥60
- Trial name
- CHANCE (NCT07172204)
- Testing
- Alternately treated with VA/low CHA regimen
- Where
- 5 sites in China
- Volunteers
- 25 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL), Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)
Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)
The purpose of this study is to test any good or bad effects of the study drug called of ibrutinib (also known as Imbruvica™). At this stage of this trial, the study is investigating whether Ibrutinib can be incorporated into the…
- Trial name
- NCT02315326
- Testing
- Ibrutinib, HD- Methotrexate (MTX), Rituximab + HD- Methotrexate (MTX)
- Where
- 7 sites in United States
- Volunteers
- 93 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Glioblastoma (GBM), Newly Diagnosed Glioblastoma Multiforme
A Study to Evaluate the Safety of a Stem Cell-Based Gene and Cell Therapy in Patients With Newly Diagnosed Glioblastoma
This is a phase I clinical trial evaluating the safety, tolerability, and maximum tolerated dose of MSC11FCD, an investigational allogeneic bone marrow-derived mesenchymal stem cell therapy expressing a suicide gene, in patients…
- Trial name
- NCT07143812
- Testing
- MSC11FCD
- Where
- South Korea
- Volunteers
- 10 people
- Sponsor
- CHA University
Newly Diagnosed Epilepsy With Focus on Seizure Frequency at Onset and Long-term Seizure Control
Predictive Value of Seizure Frequency at Onset for Long-Term Seizure Control
Epilepsy is a chronic neurological disorder characterized by recurrent unprovoked seizures, and achieving long-term seizure control remains a major therapeutic goal.
- Trial name
- NCT07343609
- Testing
- observational study (no intervention)
- Volunteers
- 100 people
- Sponsor
- Assiut University
HER2 Positive Newly Diagnosed Metastatic Esophageal, Gastric, GEJ Cancer Patients With an ECOG Performance Status of 2
Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers
Purpose: This clinical trial is designed to evaluate the safety and effectiveness of Trastuzumab Deruxtecan for patients with HER2 Positive Newly Diagnosed Metastatic Esophageal, Gastric, GEJ Cancer.
- Trial name
- NCT07126561
- Testing
- Trastuzumab Deruxtecan
- Volunteers
- 43 people
- Sponsor
- University of Chicago
Newly Diagnosed or Recurrent Metastatic Melanoma Patients, Malignant Brain Tumors
PET Imaging of Patients With Melanoma and Malignant Brain Tumors Using an 124I-labeled cRGDY Silica Nanomolecular Particle Tracer: A Microdosing Study
Current tests to detect cancer, including CAT scans and MRI scans, are limited. PET scans use special dyes that are injected into a vein and can better localize possible cancer.
- Trial name
- NCT01266096
- Testing
- PET scan with 124I-cRGDY-PEG-dots
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Childhood Cancer, Childhood Cancers
Examination of the Relationship Between Quality of Life and Caregiving Burden Among Caregivers of Pediatric Oncology Patients
Primary Aim The primary aim of this study is to determine the quality of life and caregiving burden levels of caregivers of pediatric oncology patients and to examine the relationship between these two variables.
- Conditions
- Childhood Cancer, Childhood Cancers, Caregiver Subjective Burden, Primary Caregivers of Children Newly Diagnosed With Cancer
- Trial name
- NCT07308301
- Testing
- Assessment of caregiver quality of life and burden
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- Fatma Beyza Akdeniz
Glioblastoma, Newly Diagnosed Glioblastoma
Study of Tumor Treating Fields With Hypofractionated Chemoradiotherapy in Newly Diagnosed Glioblastoma
The purpose of this study is to determine the safety and efficacy of the combination therapy of TTFields + SRS+ Temozolomide (TMZ) for newly diagnosed glioblastoma (GBM).
- Trial name
- NCT04474353
- Testing
- Optune, Gadolinium, Temozolomide
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Stanford University
Newly Diagnosed Multiple Myeloma (NDMM)
Real-world Immuno-therapy in Chinese Newly Diagnosed Multiple Myeloma Patients
To conduct a multicenter, prospective observational cohort study to investigate first-line immunotherapy patterns and clinical outcomes in NDMM patients in China.
- Trial name
- PRIMARY (NCT07296627)
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Peking University People's Hospital
Severe Aplastic Anemia, Refractory Aplastic Anemia
Safety and Efficacy of the JAK1 Inhibitor Combined With Intensive Immunosuppressive Therapy in Severe Aplastic Anemia
This study is designed as a Phase Ib/II trial. The phase Ib cohort will enroll patients with severe aplastic anemia (SAA) who have failed to respond to intensified immunosuppressive therapy.
- Conditions
- Severe Aplastic Anemia, Refractory Aplastic Anemia, Newly Diagnosed Aplastic Anemia
- Trial name
- NCT07297550
- Testing
- Golidocitinib Capsules
- Volunteers
- 42 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Newly Diagnosed, Advanced Ovarian Cancer
Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy.
- Conditions
- Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV, BRCA Mutation
- Trial name
- SOLO-1 (NCT01844986)
- Testing
- Olaparib 300mg tablets
- Where
- 177 sites in United States, Australia and 13 more
- Volunteers
- 450 people
- Sponsor
- AstraZeneca
Acute Monocytic Leukemia, Newly Diagnosed
Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia
This study is to investigate the therapeutic efficacy and side effect of venetoclax, azacytidine combined with chidamide for newly diagnosed acute monocytic leukemia patients that are ineligible for intensive chemotherapy
- Trial name
- NCT05566054
- Testing
- Chidamide, Azacitidine, Venetoclax
- Where
- China
- Volunteers
- 92 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Acute Myeloid Leukemia, Adult, Newly Diagnosed
Comparison of VA (Venetoclax, Azacitidine), VACl (VA, Cladribine), VACh (VA, Chidamide), and Alternating VACl/VACh in Newly Diagnosed Acute Myeloid Leukemia
This prospective, multi-center, randomized, controlled Phase II study is to compare the therapeutic efficacy and side effect of VACl (Venetoclax,Azacitidine,Cladribine) alternating with VACh (Venetoclax,Azacitidine,Chidamide)…
- Trial name
- NCT06532552
- Testing
- VACl, VACh, VACl Alternating With VACh
- Where
- China
- Volunteers
- 172 people
- Sponsor
- The First Affiliated Hospital of Soochow University